

• Identify the challenge and advise

At Dev4All, one of our clients was developing a pro-angiogenic molecule with promising therapeutic potential for degenerative diseases like muscular dystrophy.

The goal? Demonstrate the molecule's efficacy in promoting muscle regeneration.

The hidden pitfall? A mechanism of action that could raise safety concerns – particularly regarding tumor growth.

Therefore, we proposed early on to investigate both efficacy and safety.



Céline Martin, PhD **Head of R&D Operations**









2. Build the right alliance

- To tackle this dual objective efficacy and safety we brought together two complementary CROs within Dev4All's global network:
 - Pharmaseed validated the regenerative effect of the molecule in a murine model of muscular dystrophy.
 - Dev4All conducted an in vivo xenograft study to assess potential tumor-promoting risks of pro-angiogenic stimulation early in development

"



Eddy Pichinuk, PhD

Customer Account Manager







3 Work as one team

This collaborative approach provided our client with robust, decision-driving data, supporting both safety concerns and therapeutic promise.

Integrated preclinical strategies like this are becoming essential in the development of innovative therapies, **especially those with first-in-class mechanisms**.

We don't just run studies. We build smart, collaborative designs to clarify risk-benefit and accelerate development.



Daniel Sanchez Lopez, PhD
Solution Finder







ONE TEAM TO DRIVE ALL YOUR PRECLINICAL PROJECTS





